Clinical Trials Logo

Tricuspid Valve Insufficiency clinical trials

View clinical trials related to Tricuspid Valve Insufficiency.

Filter by:

NCT ID: NCT05892588 Recruiting - Clinical trials for Aortic Valve Stenosis

Prevalence Study of Cardiovascular Diseases in a Population ≥ 65 Years in Italy

PREVASC
Start date: June 1, 2022
Phase:
Study type: Observational [Patient Registry]

This registry is a large-scale epidemiological study (PREVASC) aimed at estimating the prevalence of symptomatic and asymptomatic valvular hear disease in men and women aged over 65 years randomly selected in Italy.

NCT ID: NCT05854095 Completed - Clinical trials for Functional Tricuspid Regurgitation

The Study for Evaluation of Acute Phase Safety and Efficacy of 'Pivot Bridge' to Short-term Treat FTR

Start date: March 13, 2023
Phase: N/A
Study type: Interventional

evaluation of safety and efficacy of 'Pivot Bridge' to short-term treat Functional Tricuspid regurgitation

NCT ID: NCT05848284 Recruiting - Clinical trials for Tricuspid Regurgitation

Clinical Safety and Efficacy of the VDyne Transcatheter Tricuspid Valve Replacement System for the Treatment of Tricuspid Regurgitation ( VISTA-US)

VISTA-US
Start date: April 1, 2024
Phase: N/A
Study type: Interventional

The purpose of this clinical study is to evaluate the safety and clinical efficacy of the VDyne System in the treatment of symptomatic severe tricuspid regurgitation (TR).

NCT ID: NCT05836493 Completed - Clinical trials for Tricuspid Regurgitation

Very Long-term (>15 Years) Results of Tricuspid Valve Repair.

Start date: October 7, 2020
Phase:
Study type: Observational

Interest in Tricuspid valve disease grew exponentially in the last years in response to an increased awareness of the poor outcome of patients with functional Tricuspid Regurgitation (TR). Earlier reports advocated for a more conservative TR management in patients undergoing left-sided heart valve surgery but more recent guidelines advised for a more aggressive TR management, as accumulating evidence demonstrates its adverse impact on long term morbidity and mortality. Several papers have been published analyzing the results of surgical tricuspid valve repair but the length of the follow-up is usually limited to 10 to 12 years. With this study the investigators aim to analyze the very long-term results (>15years) of tricuspid valve repair according to the surgical method employed for valve repair (suture vs ring annuloplasty).

NCT ID: NCT05836415 Completed - Clinical trials for Functional Tricuspid Regurgitation

Effectiveness and Durability Long-term Results of Tricuspid Annuloplasty With 3D Shaped Rings.

Start date: December 2, 2020
Phase:
Study type: Observational

Interest in tricuspid valve disease has grown exponentially over the past few years, in response to increased interest in the poor prognosis of patients with functional tricuspid regurgitation (TR). Tricuspid valve repair (TVR) using a prosthetic ring represents the first option in many centers worldwide, due to the low incidence of residual and recurrent TR and improved survival compared to suture techniques. The goal of ring annuloplasty is to restore the normal geometry of the annulus, thereby improving the coaptation of the leaflets and preventing further dilatation of the annulus. Recently, the three-dimensional geometry of the tricuspid valve has been shown and analyzed by means of data obtained from echocardiography, CT scan and magnetic resonance imaging. Normal tricuspid annulus is characterized by a more prominent part in the anteroseptal commissure area near the aortic valve and right ventricular outflow tract and a deeper part in the posteroseptal commissure area near the coronary sinus ostium . Based on these characteristics, new three-dimensional rings have been developed for tricuspid annuloplasty, such as the MC3 (Edwards Lifescience, Irvine, CA) and the Contour 3D (Medtronic, Minneapolis, MN). There are few studies concerning the short-term results of tricuspid rings implantation and almost none on the long-term, therefore this study aims to analyze the long-term results of TVR by implantation of the two new prosthetic ring models mentioned above. The aim of this study is the long-term analysis of the results of tricuspid annuloplasty with three-dimensional rings in patients with functional IT.

NCT ID: NCT05825898 Enrolling by invitation - Clinical trials for Tricuspid Regurgitation

Outcome of Patients With Severe Functional TR According to Medical, Transcatheter or Surgical Treatment

TRIGISTRY
Start date: September 1, 2022
Phase:
Study type: Observational

Tricuspid regurgitation (TR) is a public health problem: moderate / severe TR are common, especially in ageing populations, and affect 4% of the population >75 years old, totaling approximately 1.6 million in the US and 3 million in Europe. TR is associated with an increased risk of mortality and morbidity. Contrasting with TR prevalence and the magnitude of the problem, the vast majority of patients are medically treated with diuretics to relieve their symptoms and a curative surgical treatment for isolated severe TR is seldom performed. Reluctance to perform an ITVS can be explained in the one hand by the limited evidence that TR correction improves outcomes and on the other hand, ITVS is associated to high observed in-hospital mortality rates (≈ 10% remarkably consistent in most series across the literature). Severity of the clinical presentation is the main predictor of outcome after surgery. The TRI-SCORE, is a dedicated, simple and accurate risk score model to predict in-hospital mortality after ITVS that could guide the clinical decision-making process at the individual level. Excellent outcomes can be achieved when patients present with low TRI-SCORE. These results suggest adopting a more pro-active approach for TV interventions, and to intervene earlier in the course of the disease in patients with severe isolated TR, irrespective of TR mechanism / etiology, before the occurrence of advanced / irreversible consequences such as severe RV dilatation / dysfunction, renal and liver failure, and intractable heart failure. Recently transcatheter tricuspid valve interventions (TTVI) have emerged recently as a less invasive option to surgery to cure patients with TR. What is the best treatment between medical, surgical or transcatheter therapy to consider and the best timing for each patient are not clearly defined. The aim of the study is to compare outcome of patients with significant functional TR according to medical, transcatheter or surgical treatment after matching per TRISCORE.

NCT ID: NCT05820516 Not yet recruiting - Clinical trials for Severe Tricuspid Valve Regurgitation

Patients With Severe TrIcuspid Regurgitation After triCvALve System Implantation

CRITICAL
Start date: May 2023
Phase:
Study type: Observational [Patient Registry]

International Registry to collect patients with severe TR undergoing TricValve implantation from multiple Italian and European centers, aimed at: - Assessing the effect of TricValve implantation on cardiovascular and all-cause mortality, HF rehospitalization, renal function, functional capacity and quality of life. - Clarifying the haemodynamic effects of TricValve implantation and investigating their pathophysiological implications.

NCT ID: NCT05817695 Recruiting - Bradycardia Clinical Trials

Cardiac Synchronization and Tricuspid Regurgitation With Leadless Pacemaker

MICRA-SYNK
Start date: March 1, 2022
Phase:
Study type: Observational [Patient Registry]

Comparison of cardiac synchronization and tricuspid regurgitation with or without leadless pacemaker pacing in different site

NCT ID: NCT05797519 Recruiting - Clinical trials for Tricuspid Regurgitation

Clinical Safety and Efficacy of the VDyne Transcatheter Tricuspid Valve Replacement System for the Treatment of Tricuspid Regurgitation

VISTA
Start date: March 1, 2023
Phase: N/A
Study type: Interventional

The purpose of this clinical study is to evaluate the safety and clinical efficacy of the VDyne System in the treatment of moderate to severe tricuspid regurgitation (TR).

NCT ID: NCT05784883 Recruiting - Clinical trials for Tricuspid Regurgitation

Tricuspid Regurgitation in the ElderlY

TREY
Start date: August 1, 2022
Phase:
Study type: Observational

Tricuspid regurgitation (TR) is the second most common VHD after MR. Its prevalence also increases with age, with an estimated incidence of up to 6% in elderly population. When adjusted to age (among other confounders), survival is worse for patients with moderate and severe TR. We aim to explore the prevalence, mechanisms, and clinical implications of tricuspid valve regurgitation in elderly subjects screened at a tertiary center in Cairo, Egypt.